Analyst firms · Morgan Stanley · AKRO

Morgan Stanley AKRO price target and rating history

Akero Therapeutics Inc. (AKRO) · Health Care

Morgan Stanley rates Akero Therapeutics Inc. (AKRO) Overweight with a $65 price target, as of its latest action on Jan 27, 2023. It has published 3 rating actions on AKRO since October 2021, including 1 upgrade and 1 downgrade.

Current rating
Overweight
Price target
$65
Median target, all firms
Too few
Actions on AKRO
3

Morgan Stanley price target on AKRO

$65$46$2720222023202420252026
Morgan Stanley price target on AKRO, each point a stated target, October 2021 to January 2023.

Every Morgan Stanley rating on AKRO

Questions about Morgan Stanley and AKRO

What is Morgan Stanley's price target for AKRO?
Morgan Stanley's latest stated price target for Akero Therapeutics Inc. (AKRO) is $65, from its action on Jan 27, 2023.
What is Morgan Stanley's rating on AKRO?
Morgan Stanley rates AKRO Overweight, a bullish rating, as of Jan 27, 2023.
When did Morgan Stanley last change its view on AKRO?
On Jan 27, 2023, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $40 to $65.

More AKRO rating histories

All Morgan Stanley ratingsAKRO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.